Sound Pharmaceuticals (SPI-5557 & SPI-1005)

FX-322 just broke my heart, but I'm already in love again. I have to give myself time and resist the urge to get into a new hearing drug relationship too soon off the rebound.

 

Ebselen is probably the only clinical stage drug I'm still keeping my eyes on.

 

I would add OTO-413 to the list.

 

There's a number of promising drugs in the pipeline. I think the issue is timeline. Within 20 years, there will probably be quite a few major QoL improvers.

 

FX-322 was great as it had the promise to cure the problem at (one of) its roots and also because it was being developed rapidly.

After the disaster with FX-322, we should lower our expectations.

SPI-1005 will at most alleviate our problems, but not cure them. The beauty of SPI-1005, on the other hand, is that one can immediately try it out...

 

I don't disagree, but I'm not going to invest my emotional health in a drug that won't be available for another one to two decades.

 

I got maybe two years in me. Maybe. For me, it’s either some improvement via Ebselen or game over.

 

Do we know when Phase 3 will be completed?

 

I think Phase 3 has not even started, it’s premature to say about completion date.

 

As far as I know it has not even started yet. According to this website it will probably be completed in April 2023...

 

As a guy who actually attempted to commit suicide and failed, I would not recommend it. I suffer as bad as anyone here and it's not worth it. Figure out a way to deal with it.

 

Update on clinical trial dates for COVID-19:

Start May 2021, end June 2022.

Source:
https://clinicaltrials.gov/ct2/show/NCT04483973

Just another piece of bad news.

 

Sorry all, another refugee from the FX-322 thread here...

Having worked that thread for over year and jumping ship to skim read the last few pages here... It seems that this drug has had good results and is even oral!

In my mind this is even better than an injection because... No injection.

I recall a concern with FX-322 was EHF / penetration. Do we have indication that this drug acts across all frequencies?

 

I think it should act on all frequencies. The drug gets really good systemic penetrance. Crosses both the BBB and Blood/Cochlear barrier well. I don't think everyone will likely get the same benefit from it since I think it will depend on a lot of individual inflammatory factors. That's just my suspicion. Would be great if it did work for everyone.

I think it holds great promise in preventing spikes and new/further damage for pretty much everyone, though.

 

I have devoured so many of your posts that it feels like conversing with a celebrity!

I am an engineer, not a scientist, but digested the 2009 paper on the development of Ebselen. I can't find the 2021 February paper using my sources.

The 2009 paper suggests, like you did, that the primary thrust is prevention, not cure. Has the emphasis on cure increased since that point, or is it wishful thinking on my part?

 

Sorry if this is a dumb question, but I'm also a refugee from the FX-322 thread here.

What exactly is SPI-1005? According to what I have read, it is a treatment for COVID-19, currently in Phase II or III clinical trials.

How come this drug can help tinnitus?

 

I think it will be pretty universally effective as a preventative but as far as treating tinnitus, I think it will have some benefit in most people but a dramatic benefit in a certain segment.

You aren't fixing an underlying cause, you are attenuating the after effects.

However, I think people with severe tinnitus might especially benefit in breaking the stress-glutamate and dynorphin release--tinnitus--further stress, perpetuating worse tinnitus cycle. So they could possibly benefit the most.

This is just my take and I would love to hear other opinions.

 

So it should put us at a spikeless baseline? In theory.

 

Not really, that's always been the timeline.

 

It has a lot of effects. That seems to be something the drug could be capable of for sure.

 

Here's the full February 2021 paper.

 

Oh that's awesome, my spikeless baseline is great, I feel completely comfortable with it.

 

I am the opposite, I never have spikes, just changes in attitude when it gets too much to bear...

I guess this means that I am in the pool of people it probably won't work for

 

Well, this drug is extremely complex so I'm mostly speculating but if yours is severe enough to be "too much to bear" at times I think you likely have more of a locally inflammatory component than you might otherwise. Just my opinion.

 

Hey who knows really, it could work wonders for you and do nothing for me. Don't knock it till you try it!

 

No, originally the trial was supposed to end in April 2021.

 

You and me both.

Still want "the goop" too, though.

 

Damn, I thought they were going to start Phase 3 but the ClinicalTrials.gov website states Phase 2.

 

Phase 3 for Meniere's (ends 2023).
Phase 2 for COVID-19 (ends 2022).